• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, September 11, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

LA BioMed researcher honored for contributions to medicine

Bioengineer by Bioengineer
June 8, 2017
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: LA BioMed

LOS ANGELES – (June 8, 2017) – The Medical Mycology Society of the Americas has honored John E. "Jack" Edwards, Jr., MD, an LA BioMed lead researcher, as the winner of the 2017 Rhoda Benham Award. The award is given "to an individual from the Americas for continuous outstanding or meritorious contributions to medical mycology," which is the study of fungal diseases.

"Congratulations to Dr. Edwards for this important recognition of his many accomplishments and contributions to this field of scientific study," said David I. Meyer, PhD, LA BioMed president and CEO. "For more than three decades, Dr. Edwards has been dedicated to tackling deadly infectious and fungal diseases, providing the leadership at LA BioMed and in the larger scientific community on critical research that holds great promise for effective vaccines and therapies."

Dr. Edwards' research focuses on understanding the cellular and molecular mechanisms of antimicrobial host defense, principally those caused by the fungus Candida, one of the most common causes of life-threatening blood infections in hospitalized patients. With his work he hopes to dramatically advance the development of new anti-fungal agents and immunotherapies to prevent and treat life-threatening infections.

Dr. Edwards, together with his group of colleagues, founded NovaDigm Therapeutics to translate the three decades of research into products that will prevent or treat serious infectious diseases. NovaDigm is developing innovative immunotherapeutics and vaccines to protect patients from fungal and bacterial disease, which can be recurrent, drug-resistant and in many cases, life-threatening. NovaDigm's lead development candidate, NDV-3A, is the first vaccine to demonstrate efficacy for an opportunistic fungus in an exploratory, placebo controlled trial.

In addition, Dr. Edwards has served as a focal member of the National Institutes of Health Mycoses Study Group, overseeing numerous clinical trials in antifungal strategies. He's received several honors for his work, including recognition as an LA BioMed Legend.

He has served on several prestigious panels, including as chairman of the Board of Scientific Counselors of the Clinical Center at the National Institutes of Health. He is the former acting chairman of the Anti-Infective Advisory Committee of the Food and Drug Administration. He has also served as an elected counselor for the International Immunocompromised Host Society and the Infectious Disease Society of America (IDSA) as well as a member of the IDSA Antimicrobial Availability Task Force.

In addition to his work at LA BioMed, Dr. Edwards is an emeritus distinguished professor of medicine at the David Geffen School of Medicine at UCLA and a former chief of the Division of Infectious Disease at Harbor-UCLA Medical Center.

###

About LA BioMed

Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved treatments and therapies for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center.

LA BioMed's technologies have helped to generate numerous global medical breakthroughs, including the invention of the modern cholesterol test, the conception and development of the modern-day U.S. paramedic model of emergency patient care, the first isolation and administration of a lung surfactant to treat premature babies, the FDA-approved drug Kybella® for submental fullness, the FDA-approved drug Aldurazyme® for a Mucopolysaccharidosis, the development of low-cost antiseptic eye drops that prevented blindness in hundreds of thousands of newborns in developing countries and an effective treatment for Sickle Cell disease. For more information, please visit http://www.LABioMed.org

Media Contact

Laura Mecoy
[email protected]
310-546-5860
@labiomed52

http://www.LABioMed.org

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Poly-L-Histidine-Coated Nanoparticles for Targeted Doxorubicin Delivery

September 11, 2025

Barriers to Video Visits for Non-English Patients

September 11, 2025

Smart ROS Nanoplatform Boosts Targeted Cancer Therapy

September 11, 2025

Creating AI Companions for Caregiver Role Transitions

September 11, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    152 shares
    Share 61 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    64 shares
    Share 26 Tweet 16
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Poly-L-Histidine-Coated Nanoparticles for Targeted Doxorubicin Delivery

Revolutionary Ion Exchange Membranes for Arsenic Removal

PATZ1: Key Player in Tumorigenesis and Metabolism

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.